The Chemical Data

TEAM Technologies Acquires TAG3

TEAM Technologies Acquires TAG3 Engineering to Expand Medical Device Capabilities

Arlington Capital Partners a Washington, D.C.–based private investment firm with a focus on government-regulated industries, announced today that its portfolio company TEAM Technologies (“TEAM Tech”) has acquired TAG3 Engineering, LLC (“TAG3”). TEAM Tech is a leading provider of end-to-end outsourced…

Read MoreTEAM Technologies Acquires TAG3 Engineering to Expand Medical Device Capabilities
Ollin Biosciences Launches to Advance Ophthalmology Therapies

Ollin Biosciences Launches to Advance Ophthalmology Therapies

Ollin Biosciences Launches with $100 Million Financing to Advance Next-Generation Ophthalmology Therapies Ollin Biosciences, Inc., a newly established clinical-stage biopharmaceutical company, announced its launch with an initial $100 million financing round led by ARCH Venture Partners, Mubadala Capital, and Monograph…

Read MoreOllin Biosciences Launches to Advance Ophthalmology Therapies
Prota’s PRT120 Study Wins EAACI Prize

Prota’s PRT120 Study Wins EAACI Prize for Long-Term Peanut Allergy Remission

Prota Therapeutics Pty Ltd., a clinical-stage biotechnology company developing novel oral immunotherapy (OIT) treatments for food allergies, today announced that clinical research conducted in partnership with the Murdoch Children’s Research Institute (MCRI) was awarded a prestigious prize at the 2025…

Read MoreProta’s PRT120 Study Wins EAACI Prize for Long-Term Peanut Allergy Remission
Apollo’s Camoteskimab Meets Phase 2a Endpoint in Atopic Dermatitis

Apollo’s Camoteskimab Meets Phase 2a Endpoint in Atopic Dermatitis

Apollo Therapeutics Reports Positive Phase 2a Results for Camoteskimab in Atopic Dermatitis Apollo Therapeutics, a leading portfolio biopharmaceutical company, announced today positive topline results from its Phase 2a CHAMELEON trial evaluating camoteskimab, an investigational anti-IL-18 monoclonal antibody, in patients with…

Read MoreApollo’s Camoteskimab Meets Phase 2a Endpoint in Atopic Dermatitis
Areteia Reports Positive Phase III Results

Areteia Reports Positive Phase III Results for Oral Dexpramipexole in Eosinophilic Asthma

Areteia Reports Positive Phase III Results for Oral Dexpramipexole in Eosinophilic Asthma Areteia Therapeutics, Inc. announced today that its Phase III EXHALE-4 clinical trial has met key efficacy and safety endpoints for dexpramipexole, an investigational oral therapy being developed as…

Read MoreAreteia Reports Positive Phase III Results for Oral Dexpramipexole in Eosinophilic Asthma